-
The best pharmaceutical companies in the hearts of American employees: Horizon, Genentech, and AbbVie are among the top three
Time of Update: 2021-04-28
In this year's industry survey, GreatPlacetoWork compiled the annual ranking of Fortune by using an anonymous survey of more than 825,000 employees from the US medical and pharmaceutical industries.
"Reference source: Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll
-
Sihuan Biotechnology received a civil complaint involving three securities misrepresentation liability disputes
Time of Update: 2021-04-28
On March 20, Sihuan Biological issued an announcement stating that the company received a civil complaint and response from the Nanjing Intermediate People’s Court (2021) Su01 Minchu No.
, Kunshan Venture Holding Group Co.
, and Kunshan Venture Capital Co.
-
China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States
Time of Update: 2021-04-28
The institute stated that this indicates that the safety and effectiveness of new coronavirus-specific antibody drugs with China's independent intellectual property rights have been recognized by the world.
-
Newest | These 20 best selling drugs
Time of Update: 2021-04-28
11Hospital market, Top 20 drugsHospital market, Top 20 drugsAccording to the full-year data information of the PDB (PDB) in 2020, affected by the new crown epidemic, the market sales of sample hospita
-
Wu Huaifeng, director and secretary of the board of directors of Donge Ejiao, resigns
Time of Update: 2021-04-28
Due to personal reasons, Wu Huaifeng applied to resign as a director of the company, secretary of the board of directors and member of the audit committee of the board of directors.
After resignation, Wu Huaifeng will continue to serve as the company's senior vice president.
-
A commonly used OTC nationwide recalled pharmacy is suspended from sale
Time of Update: 2021-04-28
The Sichuan Provincial Food and Drug Administration requires that all municipal (prefecture) market bureaus and inspection branches of the Provincial Food and Drug Administration immediately supervise and urge drug dealers and users within their jurisdictions to take risk control measures such as suspension of sales and use and removal of the above-mentioned products, and assist in doing a good job Relevant work on drug recalls and strengthen risk monitoring of the product.
-
A batch of large varieties meets the conditions of the fifth batch of centralized procurement
Time of Update: 2021-04-28
With the gradual acceleration of the consistency evaluation of injections, more and more varieties will meet the requirements for centralized procurement, or may be included in the upcoming fifth batch of national centralized procurement.
-
The first FDA approved pericarditis therapy! IL-1 inhibitors are expected to change the treatment paradigm
Time of Update: 2021-04-28
S. FDA has approved the company’s IL-1 inhibitor Arcalyst (rilonacept) to be marketed for the treatment of patients over 12 years of age with recurrent pericarditis and to reduce the risk of recurrence of pericarditis.
"Reference materials:[1] Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis.
Retrieved March 18, 2021, from Kiniksa-Announces-FDA-Approval-of-ARCALYST-rilonacept-for-Recurrent-Pericarditis.
-
What is the production capacity of China's antibody drugs? Can the situation of key equipment and materials be broken by import?
Time of Update: 2021-04-28
In recent years, China's antibody drug commercialization production capacity has made considerable progress, but the overall production capacity is insufficient, the production capacity is scattered, the process experience is lacking, the core equipment and materials have not been localized, and the production talent echelon has not yet formed.
-
Process|Asymmetric synthesis solution of alogliptin preparation process
Time of Update: 2021-04-28
The process uses compound 2 as a raw material, and firstly undergoes a substitution reaction with intermediate 3 under alkaline conditions to obtain intermediate 4; intermediate 4 is condensed with chiral raw material 5 to obtain Alogliptin (1 ) And then benzoic acid to form the target product Alogliptin (1) benzoate.
-
Pfizer's lorlatinib receives FDA approval for first-line treatment of ALK-positive metastatic lung cancer
Time of Update: 2021-04-28
S. FDA has approved the Supplemental New Drug Application (sNDA) for Lorbrena (lorlatinib), expanding the indications to include anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients First-line treatment.
Reference materials:[1] US FDA EXPANDS APPROVAL OF PFIZER'S LORBRENA® AS FIRST-LINE TREATMENT FOR ALK-POSITIVE METASTATIC LUNG CANCER.
-
The new version of the medical insurance catalog implements three PD-1 prices, and the annual fee of Hengrui Erica is less than 10,000
Time of Update: 2021-04-28
It is also understood that the new price of BeiGene’s PD-1 tislelizumab (trade name: Beizian) before medical insurance reimbursement has dropped to 2180 yuan per tube, a drop of up to 80%, and the annual treatment cost is only less than 7.
-
New ADC drug Padcev applies for marketing in Japan: treats patients refractory to PD-(L)1 inhibitors
Time of Update: 2021-04-28
The Phase 3 EV-301 confirmatory trial was conducted in adult patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based chemotherapy and a PD-1/L1 inhibitor, comparing Padcev with chemotherapy.
-
Vertex begins Phase 1/2 clinical trial of VX-880 experimental treatment
Time of Update: 2021-04-28
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
-
Anhui initiates emergency procurement negotiations on Zhifei Biotech's new crown vaccine
Time of Update: 2021-04-28
On March 22, the Anhui Provincial Center for Disease Control and Prevention issued the "Announcement on Emergency Procurement Negotiations for Emergency Use of Recombinant Novel Coronavirus Vaccines (CHO Cells) in Anhui Province".
Vaccine (CHO cell), the relevant manufacturer is Anhui Zhifeilongkoma Biopharmaceutical Co.
-
Nefecon, a new drug for primary IgA nephropathy, applies for listing in the United States!
Time of Update: 2021-04-28
The Swedish biopharmaceutical company Calliditas Therapeutics recently announced that it has submitted a new drug application (NDA) for Nefecon (budesonide) to the US Food and Drug Administration (FDA), a new oral formulation that targets down-regulation of IgA1 for the treatment of primary IgA.
-
Zhejiang Medicine: Teicoplanin for injection passed the consistency evaluation
Time of Update: 2021-04-28
2g (200,000 units) of teicoplanin for injection approved and issued by the National Medical Products Administration, and approved the drug to pass the generic drug Consistency evaluation of quality and efficacy.
At present, there are 3 domestic approved manufacturers of teicoplanin for injection, of which North China Pharmaceutical Co.
-
Pharmacy approval is fully liberalized
Time of Update: 2021-04-28
There is no fastest way to open a pharmacy, only faster. One province is clear, allowing pharmacies to approveOne province is clear, allowing pharmacies to approveOn March 4, the Anhui Provincial Food
-
Dongyangguang: Application for drug registration of insulin aspart injection has been accepted
Time of Update: 2021-04-28
(hereinafter referred to as "Dongyang Pharmaceutical") insulin aspart injection had received the "Notice of Acceptance" issued by the State Food and Drug Administration.
According to Ai Kunwei data, in 2019, China's diabetes drug sales amount is approximately 3.
-
Authorization to introduce the dilemma again! The product has been approved for listing but was broken up by US$20 million
Time of Update: 2021-04-28
The rights that Beihai Kangcheng acquired at the time was an exclusive license agreement for the development and commercialization of lenatinib in mainland China, Taiwan, Hong Kong and Macau.
